We prospectively examined the use of hormone replacement therapy in relation to breast cancer incidence in a cohort of women 30 to 55 years of age in 1976. During 12 years of follow-up (480,665 person-years) among postmenopausal women, 1,050 incident cases of breast cancer were documented. Overall, past users of replacement estrogen were not at increased risk. After adjustment for established risk factors, type of menopause, age at menopause, and current age, the rate ratio (RR) was 0.91, 95 percent confidence interval (CI) = 0.78–1.07. the risk of breast cancer was elevated significantly among current users (RR = 1.33, CI = 1.12–1.57); after adjusting for age, we observed no evidence of increasing risk with increasing duration of use among current users (P trend = 0.41), or among past users (P trend = 0.46). Women currently using unopposed estrogen (RR = 1.42, CI = 1.19–1.70), estrogen and progesterone (RR = 1.54, CI = 0.99–2.39), or progesterone alone (RR = 2.52, CI = 0.66–9.63), were all at increased risk of breast cancer compared with never users. These data suggest that long-term past use of estrogen replacement therapy is not related to risk, that current estrogen use increases risk of breast cancer to a modest degree, and that the addition of progesterone does not remove the increased risk observed with current use of unopposed estrogen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990; 264: 2648–53.
Romieu I, Willett WC, Colditz GA, et al. A prospective study of oral contraceptive use and the risk of breast cancer in women. JNCI 1989; 81: 1313–21.
London SJ, Colditz GA, Stampfer MJ, et al. A prospective study of relative weight, height, and risk of breast cancer. JAMA 1989; 262: 2853–8.
Colditz GA, Stampfer MJ, Willett WC, et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort of women. Am J Epidemiol 1987; 126: 319–25.
Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol 1984; 119: 837–9.
Mantel N. Chi-square test with one degree of freedom: extension of the Mantel-Haenszel procedure. J Am Stat Assoc 1983; 56: 690–700.
Cox DR. Regression models and life-tables. JR Stat Soc (B) 1972; 34: 187–220.
Gambrel RD, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progesterone users. Obstet Gynecol 1983; 62: 435–43.
Hayward RA, Shapiro MF, Freeman HF, Corey CR. Who gets screened for cervical and breast cancer? Results from a national survey. Arch Int Med 1988; 148: 1177–81.
Heath CW, Funk DJ, Strickland R, et al. Trends in screening mammography for women 50 years of age and older—Behavioral Risk Factor Surveillance System, 1987. MMWR 1989; 38: 137–40.
Mills PK, Beeson WL, Phillips RL, Fraser GE. Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer 1989; 64: 591–7.
Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832–8.
Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293–7.
Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986; 54: 825–32.
Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985–90.
Sacks FM, Walsh BW. The effects of reproductive hormones on serum lipoproteins: unresolved issues in biology and clinical practice. Ann NY Acad Sci 1990; 592: 272–85.
Henderson BE, Ross RK, Paganini-Hill A, Mack TM. Estrogen use and cardiovascular disease. Am J Obstet Gynecol 1986; 154: 1181–6.
Additional information
The authors are with the Nurses' Health Study, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA; and Harvard Medical School, Boston, MA, USA. Address correspondence to Dr Colditz, Channing Laboratory, 180 Longwood Ave., Boston, MA 02115-5899, USA. Supported by research grant CA40356 from the National Cancer Institute, NIH, Department of Health and Human Services. Dr Colditz is supported by an American Cancer Society Faculty Research Award FRA-398.
Rights and permissions
About this article
Cite this article
Colditz, G.A., Stampfer, M.J., Willett, W.C. et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 3, 433–439 (1992). https://doi.org/10.1007/BF00051356
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00051356